This cohort study compares risks of thromboembolic stroke, intracranial hemorrhage, major extracranial bleeding, and mortality in Medicare beneficiaries with nonvalvular atrial fibrillation who initiated dabigatran or rivaroxaban therapy for stroke prevention.
This retrospective cohort study reports a higher incidence of major bleeding and a higher risk of gastrointestinal bleeding with dabigatran.
This cross-sectional study demonstrates that opioid use is associated with an increased prevalence of atrial fibrillation.
Soliman and colleagues examine the risk of incident myocardial infarction (MI) associated with atrial fibrillation (AF). In a related editorial, Dukes and Marcus further explore the association between MI and AF.